ATTR Amyloidosis Treatment Market Size, Trends, and Growth Forecast 2026-2033

Author : kajal patil | Published On : 26 May 2026

The ATTR Amyloidosis Treatment market is witnessing rapid advancements due to increasing awareness and innovations in therapeutic solutions aimed at this rare but fatal disorder. The evolving treatment landscape is supported by breakthroughs in molecular targeting and personalized medicine, driving significant business growth and expanding the market scope.

Market Size and Overview

The ATTR Amyloidosis Treatment Market is estimated to be valued at USD 4.14 Bn in 2025 and is expected to reach USD 7.52 Bn by 2032, growing at a compound annual growth rate (CAGR) of 8.9% from 2025 to 2032.

This robust market growth is fueled by rising prevalence of amyloidosis and improving diagnostic capabilities. Increasing investments in research and development have expanded market opportunities and shifted industry trends toward more effective and safer therapeutic options. The ATTR Amyloidosis Treatment Market Report highlights expanding market revenue streams due to increasing adoption of novel treatments and enhanced healthcare infrastructure worldwide.

Market Drivers
- Rising Prevalence of ATTR Amyloidosis: The primary driver of market growth is the increasing global prevalence of transthyretin amyloidosis, especially in aging populations. For instance, in 2024, data from major healthcare organizations indicated a surge in diagnosed cases owing to improved awareness and diagnostic accuracy. This trend has driven market companies to innovate targeted therapies, expanding market share and fueling strategic market growth.
- Example: In 2025, the launch of a novel gene-silencing drug by a leading biotech player brought significant attention as it demonstrated substantial efficacy in clinical trials, further boosting market dynamics.

PEST Analysis

- Political: Regulatory approvals in major markets like the U.S. and Europe have accelerated in 2024 with agencies prioritizing orphan drug designations for ATTR amyloidosis treatments, facilitating faster market access and expanding market scope.
- Economic: Increasing healthcare expenditure and government funding for rare diseases in 2025 are strengthening market revenue streams and encouraging market players to enhance portfolio diversification strategies.
- Social: Growing patient awareness programs and advocacy groups in regions including North America and Europe in 2024 have improved patient diagnosis rates, influencing market trends and fulfilling unmet market opportunities.
- Technological: Breakthroughs in RNA interference (RNAi) therapies and CRISPR-based gene editing have revolutionized treatment approaches in early 2025, increasing market growth by enabling innovative product launches and collaborations within the market companies segment.

Promotion and Marketing Initiatives
Pharmaceutical companies have increasingly adopted patient-centric educational campaigns combined with digital marketing strategies to boost treatment adoption. For example, in 2025, a key player successfully implemented a global awareness campaign on ATTR amyloidosis, partnering with medical institutions and patient advocacy groups. This initiative significantly enhanced market share and improved brand visibility among healthcare professionals, leading to increased prescriptions and faster acceptance of new therapies within the market forecast span.

Key Players and Recent Strategies
- Pfizer Inc.
- Alnylam Pharmaceuticals, Inc.
- Ionis Pharmaceuticals, Inc.
- Eidos Therapeutics, Inc.
- Akcea Therapeutics, Inc.

Recent strategic developments include:
- In 2025, Pfizer expanded its pipeline with a novel ATTR amyloidosis treatment candidate entering advanced clinical phases, projecting considerable market revenue growth.
- Alnylam Pharmaceuticals launched a next-generation RNAi therapy in early 2024, strategically growing their market share in North America and Europe.
- Ionis Pharmaceuticals entered strategic partnerships in 2025 focusing on co-developing combination therapies targeting ATTR amyloidosis, enhancing their market presence and driving business growth.
- Eidos Therapeutics pursued licensing agreements in 2024, facilitating faster treatment commercialization, positively impacting competitive positioning.
- Akcea Therapeutics achieved regulatory milestones in 2025, allowing product launches in previously untapped markets, broadening market scope and overall industry share.

FAQs

1. Who are the dominant players in the ATTR Amyloidosis Treatment market?
The dominant players include Pfizer Inc., Alnylam Pharmaceuticals, Ionis Pharmaceuticals, Eidos Therapeutics, and Akcea Therapeutics, all actively expanding their pipelines with innovative treatment options and strategic collaborations.

2. What will be the size of the ATTR Amyloidosis Treatment market in the coming years?
The market size is expected to grow from USD 4.14 billion in 2026 to USD 7.52 billion by 2032, reflecting an 8.9% CAGR driven by new drug approvals and enhanced treatment adoption.

3. Which end-user segment has the largest growth opportunity in the ATTR Amyloidosis Treatment market?
Hospitals and specialty clinics are the largest end-user segments due to increasing diagnosis rates and improved treatment availability, leading to higher market revenue and expanding industry size.

4. How will market development trends evolve over the next five years?
Trends will focus on personalized medicine, gene-silencing therapies, and improved diagnostic techniques, bolstered by patient education and regulatory support, shaping market growth strategies and intensifying competition.

5. What is the nature of the competitive landscape and challenges in the ATTR Amyloidosis Treatment market?
The market features intensifying competition with key players investing heavily in R&D and strategic partnerships. Challenges involve high treatment costs and regulatory complexities but ongoing innovation mitigates these restraints.

6. What go-to-market strategies are commonly adopted in the ATTR Amyloidosis Treatment market?
Common strategies include global awareness campaigns, collaborations with healthcare providers, expedited regulatory pathways, and portfolio expansions emphasizing precision therapies to maximize market opportunities and business growth.

‣ Get more insights on: ATTR Amyloidosis Treatment Market

‣ Get this Report in Japanese Language: ATTRアミロイドーシス治療市場

‣ Get this Report in Korean Language: ATTR아밀로이드증치료시장

Author Bio:

Money Singh is a seasoned content writer with over four years of experience in the market research sector. Her expertise spans various industries, including food and beverages, biotechnology, chemical and materials, defense and aerospace, consumer goods, etc.